MedTrace Logo

Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis

NCT05183425 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-02-04

No results posted yet for this study

Summary

Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver metastasis remains poor. Tumor heterogeneity is the cause of treatment failure. In this study, we aim the investigate the consistency of drug sensitivity for the matched primary and metastatic tumor in patients with liver metastasis.

Conditions

  • Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05183425 on ClinicalTrials.gov